Hormonal
Semaglutide (2.4 mg/week) provides significantly better economic value for weight reduction than liraglutide (3 mg/day), with a lower cost needed to treat per 1% body weight reduction.
If you are choosing between semaglutide and liraglutide for weight loss in the US, semaglutide is the more economically efficient option. It achieves nearly double the weight loss (12.4% vs 5.4%) for a lower cost per percentage point of weight lost, despite having a higher total therapy cost. The weekly injection schedule may also improve convenience and adherence compared to daily injections.
Semaglutide provides significantly better value for money than liraglutide for weight reduction.
Why this rating
Based on two large, high-quality RCTs (STEP 1 and SCALE) with similar baseline characteristics, though not a direct head-to-head trial.
Source
Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis
Joseph Azuri et al. · Obesity · 2023
DOI 10.1002/oby.23752
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →